真实世界环境中类风湿关节炎患者两年内糖皮质激素使用轨迹分析
在RCVRIC纵向队列184例类风湿关节炎患者中,44%基线使用糖皮质激素(GC);GC使用者可识别出两条轨迹:25%在一年内停用GC,75%维持低剂量GC至2年;校正HAQ、GC疗程和甲氨蝶呤使用后,维持轨迹组6个月和1年EULAR良好应答率显著更低。
要点
- 真实世界类风湿关节炎患者中近半数使用糖皮质激素。
- GC使用者中75%维持低剂量GC至2年,25%在一年内停用。
- 校正后维持GC轨迹组6个月和1年EULAR良好应答率更低。
核心结论
- 真实世界实践中近半数已确诊类风湿关节炎患者使用GC,多数GC使用者长期维持低剂量GC至2年。
- 结果凸显停用GC的困难、GC疗效-安全性平衡缺乏共识以及个体化最佳减量方案的必要性。
研究设计与样本
- 基于RCVRIC纵向队列的真实世界研究,纳入因启动或更换生物制剂改善病情抗风湿药而入选的类风湿关节炎患者184例。
- 基线比较GC使用情况,GC使用者中采用基于组的轨迹模型分析2年随访期间GC剂量轨迹,并比较轨迹间特征与结局。
主要发现
- 184例患者(RA病程4.2年(1.3; 12.6),DAS28-CRP 4.24±2.14)中81例(44%)使用GC。
- GC使用者显著年龄更大、CRP和HAQ更高、高血压更多、腰椎T值更低,但活动度和侵蚀评分相似。
- GC使用者中识别出两条轨迹:轨迹1(n=20,25%)第一年内停用GC,轨迹2(n=61,75%)2年时维持低剂量GC。
- 轨迹2与更高HAQ、更长GC疗程和更少联用甲氨蝶呤显著相关。
- 校正HAQ、GC疗程和MTX使用后,GC维持轨迹组6个月和1年EULAR良好应答更少(38.3% vs 81.3%,p=0.03;42.0% vs 82.4%,p=0.02);轨迹2中注意到糖尿病、骨折和体重指数增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse glucocorticoid (GC) use and trajectories in a real-life cohort of rheumatoid arthritis (RA). METHODS: Patients with RA included in the longitudinal RCVRIC cohort for initiating or changing biological disease-modifying antirheumatic drugs, were compared for the use of GCs at baseline. Among the GC users, the GC dose was analysed over 2 years of follow-up by group-based trajectory models. Characteristics and outcomes were compared between the trajectories. RESULTS: Among the 184 patients (RA duration 4.2 years (1.3; 12.6), Disease Activity Scores (DAS)28-C reactive protein (CRP) 4.24±2.14), 81 (44%) were on GCs. The GC users were significantly older, had higher CRP and Health Assessment Questionnaire (HAQ), more hypertension and lower lumbar T-score, but similar activity and erosive scores. Among the GC users, two trajectories were identified: trajectory 1 (n=20, 25%) with GC discontinuation in the first year and trajectory 2 (n=61, 75%) with maintenance of low-dose GCs at 2 years. Trajectory 2 was significantly associated with higher HAQ, a longer GC duration and a less frequent methotrexate association. After adjustment for HAQ, GC duration and MTX use, good EULAR responses were less frequent at 6 months and 1 year in the GC maintenance trajectory (38.3% vs 81.3%, p=0.03; 42.0% vs 82.4%, p=0.02). Diabetes, fractures and increased body mass index were noted in trajectory 2. CONCLUSION: GCs were used in almost half of patients with established RA in real-world practice. For the majority of GC users, a long-term low dose of GCs is maintained over 2 years. These results highlight the difficulties with stopping GCs, the lack of consensus for the efficacy-safety balance of GCs, and the need to individualise the best GC tapering.
引用
- Delteil A, Lambert C, Pereira B, et al. Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting. RMD Open. 2023. PMID: 37880179. doi:10.1136/rmdopen-2023-003366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。